Safety of long-term proactive management with fixed-dose combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam in patients with psoriasis vulgaris: Results of a phase III, multicenter, randomized, 52-week, vehicle-controlled trial

被引：0
|
作者：
Lebwohl, Mark [1 ]
Lacour, Jean Philippe [2 ]
Liljedahl, Monika [3 ]
Lynde, Charles [3 ]
Morch, Marie [3 ]
Snel-Prento, Anja [3 ]
Thaci, Diamant [4 ]
Warren, Richard B. [5 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Hosp Nice, Dept Dermatol, Nice, France
[3] Leo Pharma, Ballerup, Denmark
[4] Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[5] Univ Manchester, Manchester, Lancs, England
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
12797
引用
收藏
页码：AB1 / AB1
页数：1
相关论文
共 48 条
  • [41] LONG-TERM (104-WEEK) EFFICACY AND SAFETY PROFILE OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 1)
    Bird, P.
    Adebajo, A.
    Gladman, D.
    Kavanaugh, A.
    Mease, P.
    Gomez-Reino, J.
    Hall, S.
    Lespessailles, E.
    Schett, G.
    Shah, K.
    Huhu, C.
    Wollenhaupt, J.
    INTERNAL MEDICINE JOURNAL, 2015, 45 : 39 - 40
  • [42] Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
    Gladman, Dafna
    Kavanaugh, Arthur
    Mease, Philip
    Adebajo, Adewale
    Gomez-Reino, Juan
    Hall, Stephen
    Lespessailles, Eric
    Schett, Georg
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall
    Wollenhaupt, Juergen
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1283 - 1283
  • [43] Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
    Kavanaugh, Arthur
    Adebajo, Adewale O.
    Gladman, Dafna D.
    Gomez-Reino, Juan J.
    Hall, Stephen
    Lespessailles, Eric
    Mease, Philip J.
    Schett, Georg A.
    Shah, Kamal
    Teng, Lichen
    Wollenhaupt, Juergen
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [44] LONG-TERM (104-WEEK) EFFICACY AND SAFETY PROFILE OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 1)
    Adebajo, Adewale O.
    Gladman, Dafna D.
    Kavanaugh, Arthur
    Mease, Philip J.
    Gomez-Reino, Juan J.
    Hall, Stephen
    Lespessailles, Eric
    Schett, Georg
    Shah, Kamal
    Hu, ChiaChi
    Wollenhaupt, Juergen
    RHEUMATOLOGY, 2015, 54 : 133 - 133
  • [45] Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
    Edwards, Christopher J.
    Blanco, Francisco J.
    Crowley, Jeffrey
    Hu, ChiaChi
    Shah, Kamal
    Birbara, Charles A.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [46] DISEASE ACTIVITY AND SAFETY DURING LONG-TERM (104-WEEK) TREATMENT WITH APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 3)
    Edwards, C.
    Blanco, F.
    Crowley, J.
    Hu, C.
    Shah, K.
    Birbara, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 348 - 349
  • [47] Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial
    Bingham, Clifton O., III
    Mendelsohn, Alan M.
    Kim, Lilianne
    Xu, Zhenhua
    Leu, Jocelyn
    Han, Chenglong
    Lo, Kim Hung
    Westhovens, Rene
    Weinblatt, Michael E.
    ARTHRITIS CARE & RESEARCH, 2015, 67 (12) : 1627 - 1636
  • [48] Long-term results from the neoadjuvant GeparDuo trial: A randomized, multicenter, open phase III study comparing a dose-intensified 8-week schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a sequential 24-week schedule of doxorubicin hydrochloride/cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative therapy (NACT) in patients (pts) with operable breast cancer (BC).
    Kaufmann, M.
    Elermann, W.
    Schuette, M.
    Hilfrich, J.
    Blohmer, J. U.
    Gerber, B.
    Costa, S. D.
    Loibl, S.
    Nekijudova, V.
    Von Minckwitz, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345